Liquidia Corporation (NASDAQ:LQDA – Get Free Report) has been assigned an average rating of “Hold” from the twelve brokerages that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $72.85.
LQDA has been the topic of several analyst reports. Wedbush set a $58.00 price objective on Liquidia in a research note on Friday, October 2nd. Royal Bank Of Canada set a $65.00 target price on Liquidia in a research note on Thursday, October 15th. Needham & Company LLC cut their price target on Liquidia from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Stephens set a $130.00 price target on Liquidia in a research report on Friday, July 24th.
Check Out Our Latest Research Report on LQDA
Insider Buying and Selling at Liquidia
In related news, Director Stephen M. Bloch sold 235,477 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $27.13, for a total value of $6,388,491.01. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Roger Jeffs sold 32,744 shares of Liquidia stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $932,549.12. Following the completion of the transaction, the chief executive officer owned 1,125,848 shares of the company’s stock, valued at $32,064,151.04. This represents a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 566,579 shares of company stock valued at $25,746,120. 25.60% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Liquidia
A number of large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company raised its holdings in Liquidia by 63.3% during the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after purchasing an additional 22,592 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Liquidia in the 2nd quarter valued at $29,694,000. Seven Fleet Capital Management LP grew its position in shares of Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after buying an additional 51,727 shares during the last quarter. Bank of America Corp DE raised its stake in Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in Liquidia in the second quarter valued at $1,993,000. 64.54% of the stock is owned by hedge funds and other institutional investors.
Liquidia Price Performance
Liquidia stock opened at $44.99 on Friday. The firm has a market cap of $4.03 billion, a PE ratio of 32.84, a price-to-earnings-growth ratio of 0.40 and a beta of 0.61. Liquidia has a 52-week low of $22.21 and a 52-week high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The company’s 50 day moving average is $53.51 and its two-hundred day moving average is $54.26.
Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.49) EPS. On average, research analysts expect that Liquidia will post 2.05 EPS for the current fiscal year.
Liquidia Company Profile
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.
Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.
Featured Stories
- Five stocks we like better than Liquidia
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
